Up-to-date Information on
Waldenström’s macroglobulinemia



The state-of-the-art glossary for Waldenström’s macroglobulinemia.


Bendamustine in the glossary for Waldenström's macroglobulinemia

An alkylating agent (chemotherapy)

Bendamustine, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL). It is administered intravenously. Bendamustine belongs to the alkylating-agent family of anticancer agents. Its mechanism of action involves interfering with the function of DNA and RNA. Bendamustine was approved for medical use in the United States (US) in 2008, and is on the World Health Organization (WHO) List of Essential Medicines. Bendamustine is authorized for use in a number of European countries (bedamustine SmPC).

Glossary overview